Improved Survival in Subset of Advanced Pancreatic Cancer

Adding nimotuzumab to gemcitabine significantly improved survival outcomes in a subset of patients with KRAS wild-type advanced pancreatic cancer.
Medscape Medical News

source https://www.medscape.com/viewarticle/975056?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost